CLENE INC C/WTS 30/12/2025 (TO PUR COM) | 8-K: FY2025 Q1 Revenue: USD 81 K

LB filings
2025.05.07 12:03
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q1, the actual value is USD 81 K.

EPS: As of FY2025 Q1, the actual value is USD -0.09.

EBIT: As of FY2025 Q1, the actual value is USD -4.076 M.

Segment Revenue

  • Product Revenue: $64 thousand for the quarter ended March 31, 2025, compared to $44 thousand for the same period in 2024.
  • Royalty Revenue: $17 thousand for the quarter ended March 31, 2025, compared to $29 thousand for the same period in 2024.
  • Total Revenue: $81 thousand for the quarter ended March 31, 2025, compared to $73 thousand for the same period in 2024.

Operational Metrics

  • Net Loss: $0.8 million for the quarter ended March 31, 2025, compared to $11.1 million for the same period in 2024.
  • Loss from Operations: - $4.076 million for the quarter ended March 31, 2025, compared to - $9.232 million for the same period in 2024.
  • Research and Development Expenses: $1.5 million for the quarter ended March 31, 2025, compared to $5.9 million for the same period in 2024.
  • General and Administrative Expenses: $2.7 million for the quarter ended March 31, 2025, compared to $3.4 million for the same period in 2024.

Cash Flow

  • Cash and Cash Equivalents: $9.8 million as of March 31, 2025, compared to $12.2 million as of December 31, 2024.

Unique Metrics

  • Total Other Income: $3.3 million for the quarter ended March 31, 2025, compared to total other expense of $1.8 million for the same period in 2024.

Outlook / Guidance

Clene Inc. received a notice from Nasdaq regarding its common stock’s market value being below the minimum requirement for continued listing. The company has until November 3, 2025, to regain compliance, and it intends to actively monitor its stock’s market value and consider options to meet the requirement. Clene plans to submit a New Drug Application (NDA) in the fourth quarter of 2025 for potential Accelerated Approval of CNM-Au8 in ALS. The company is preparing for a meeting with the FDA in the second quarter of 2025 to finalize its statistical analysis plan for CNM-Au8 NfL biomarker data, with analysis scheduled for the third quarter of 2025.

Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.